Ocular Therapeutix Files 8-K
Ticker: OCUL · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, material-event
Related Tickers: OCUL
TL;DR
OCUL filed an 8-K, something happened but they aren't saying what yet.
AI Summary
Ocular Therapeutix, Inc. filed an 8-K on December 18, 2025, reporting an event under "Other Events." The filing does not contain specific details about the event, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates a material event has occurred for Ocular Therapeutix, Inc., requiring disclosure to investors, though the specific nature of the event is not detailed in the provided text.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which typically reports material events, but the lack of specific details in the provided text creates uncertainty about the nature and impact of the event.
Key Players & Entities
- OCULAR THERAPEUTIX, INC. (company) — Filer of the 8-K report
- December 18, 2025 (date) — Date of the report and earliest event reported
- 15 Crosby Drive Bedford, MA 01730 (address) — Principal Executive Offices
- 001-36554 (company_id) — Commission File Number
FAQ
What specific event is Ocular Therapeutix, Inc. reporting under "Other Events" in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the event reported under "Other Events."
When was this 8-K report filed with the SEC?
This 8-K report was filed on December 18, 2025.
What is the principal executive office address for Ocular Therapeutix, Inc. as listed in the filing?
The principal executive office address is 15 Crosby Drive, Bedford, MA 01730.
What is the Commission File Number for Ocular Therapeutix, Inc.?
The Commission File Number for Ocular Therapeutix, Inc. is 001-36554.
Does the filing provide any financial figures or dollar amounts related to the reported event?
No, the provided text of the 8-K filing does not include any specific dollar amounts or financial figures related to the reported event.
Filing Stats: 792 words · 3 min read · ~3 pages · Grade level 15.9 · Accepted 2025-12-18 16:30:34
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share OCUL The Nasdaq
Filing Documents
- tm2533889d1_8k.htm (8-K) — 25KB
- 0001104659-25-122564.txt ( ) — 184KB
- ocul-20251218.xsd (EX-101.SCH) — 3KB
- ocul-20251218_lab.xml (EX-101.LAB) — 33KB
- ocul-20251218_pre.xml (EX-101.PRE) — 22KB
- tm2533889d1_8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements of Ocular Therapeutix, Inc. (the "Company") regarding future expectations, plans, and prospects for the Company; statements regarding the timing of the availability of data from the Company's SOL-1 Phase 3 clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration; statements regarding the timing of the availability of audited financial results; and other statements containing the words "anticipate", "believe", "estimate", "expect", "intend", "designed", "goal", "may", "might", "plan", "predict", "project", "target", "potential", "will", "would", "could", "should", "continue", and similar expressions, all of which constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties regarding the timing, conduct and availability of data from ongoing clinical trials, including the Company's SOL-1 trial; risks associated with reliance on clinical trial sites and other third parties ; uncertainties as to the timing of the completion of the Company's financial quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company's views as of the date of this Current Report on Form 8-K. The
01 Other Events
Item 8.01 Other Events. As the Company prepares for database lock for its SOL-1 Phase 3 clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of wet age-related macular degeneration, the Company is entering a quiet period beginning December 20, 2025. The Company's next planned investor communication is expected early February 2026, with the release of its financial results for the fourth quarter and fiscal year ending December 31, 2025. At such time, the Company expects to provide an update on the timing of SOL-1 data, which remain on track for the first quarter of 2026.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OCULAR THERAPEUTIX, INC. Date: December 18, 2025 By: /s/ Donald Notman Donald Notman Chief Financial Officer and Chief Operating Officer